• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

SATA

Society for the Advancement of Transplant Anesthesia

  • Home
    • For Authors
  • About SATA
    • Committees
      • Abdominal Educational Committee
      • Bylaws Committee
        • SATA Bylaws
      • Cardiothoracic Transplant Committee
        • Cardiothoracic Transplantation Educational Task Force
      • Critical Care Medicine Committee
      • Federation Working Group
      • Fellowship Committee
      • Finance Work Group
      • Membership Committee
      • Newsletter Committee
      • Pediatric Transplant Committee
      • Practice Management Working Group
      • Quality and Standards Committee
      • Research Committee
      • TEE Working Group
      • Vanguard Committee
      • Website Working Group
  • Membership
    • Join Now
    • Gift Memberships
  • Education
    • Upcoming Events
    • Meetings
    • Education Materials
      • Article of the Month
      • Protocols / Recommendations / PBLDs
      • Educational Media
      • Transplant Fellowship Information
      • Archive
  • Research
    • SATA Seed Project Funding
    • SATA Publications
  • Newsletter
  • Careers
    • Jobs
    • Post a Job
  • Contact
  • Log In

Education

December 2022 Article of the Month

February 2, 2023 By Sergio Leave a Comment

Alcohol-associated liver disease predicts increased post-liver transplant opioid use.

Abstract:

BACKGROUND: Alcohol-associated liver disease (ALD) is a rising indication for liver transplantation (LT). Prolonged opioid use after LT leads to increased graft loss and mortality. The aim is to determine if patients transplanted with a primary diagnosis of ALD had higher risk of post-LT opioid use (p-LTOU) compared to non-ALD patients.

METHODS: This is a retrospective study of patients who underwent LT between 2015 and 2018 at Medstar Georgetown Transplant Institute. Patients with prolonged hospitalization post-LT (>90 days), death within 90 days post-LT, and re-transplants were excluded.

RESULTS: Two hundred and ninety-seven patients were transplanted, among 29% for indications of ALD. ALD patients were younger (52 vs. 56 years), more likely to be male (76% vs. 61%), Caucasian (71% vs. 44%), have higher MELD (28.8+/-8.8 vs. 25+/-8.8), and psychiatric disease than non-ALD patients (P < .05). There was no difference in pre-LT use of opioids, tobacco, marijuana, or illicit drugs between ALD and non-ALD patients. Pre-LT opioid use (OR = 11.7, P < .001), ALD (OR = 2.5, P = .01), and MELD score (OR = .95, P = .02) independently predicted 90-day p-LTOU.

CONCLUSIONS: ALD, pre-LT opioid use, and MELD score independently predict p-LTOU. Special attention should be paid to identify post-LT prolonged opioid use in ALD patients.

Comments made by Cale Kassel M.D., FASA

 

Summary:

In this retrospective study, the Johnson-Laghi et al reviewed patients undergoing liver transplantation focusing on patients with known alcoholic liver disease and previous opioid use prior to transplantation. As has been described, the use of pre-operative opioids is associated with worse outcomes in other surgical procedures. The authors sought to identify if post-LT opioid use (p-LTOU) was greater in patients with alcoholic liver disease (ALD) compared to those without alcoholic liver disease.

Patient demographic data included diagnosis of psychiatric disease, use of psychiatric medications, use of illicit drugs, use of benzodiazepines, use of marijuana, prior alcoholic rehabilitation, and legal encounters related to alcohol (DUI). Use of pre-operative opioids included use both scheduled and as needed within the three months prior to transplantation. The total dose was converted to morphine equivalents for comparison.

Overall, opioid use post-LT was more common with patients with ALD compared to those without at 30, 60, and 90 days. At 90 days, 44% of ALD patients were taking opioids compared to 27% of non-ALD patients (p = 0.004). Multi-variate logistic regression demonstrated pre-LT opioid use, primary diagnosis of ALD, and lower MELD predicted 90-day post-LT opioid use.

Further analysis showed specific risk factors for p-LTOU at 60 days to include living alone. As the authors noted, this shows the importance of good social support for patients evaluated for LT. This was not a significant variable at 90 days however.

As the authors noted, more research is needed on this topic to further identify risk factors for opioid use following LT. Additionally, this is an area for anesthesiologist involved in the listing process to add value. Opioid tapering prior to LT may provide benefit for patients. Identifying patients with any patient who take opioids, can allow for early intervention including opioid tapering.

Filed Under: Article of the Month, Education

October 2022 Article of the Month

December 5, 2022 By Sergio Leave a Comment

Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States.

Abstract:

Coronavirus disease-19 has had a marked impact on the transplant population and processes of care for transplant centers and organ allocation. Several single-center studies have reported successful utilization of deceased donors with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests. Our aims were to characterize testing, organ utilization, and transplant outcomes with donor SARS-CoV-2 status in the United States. We used Scientific Registry of Transplant Recipients data from March 12, 2020 to August 31, 2021 including a custom file with SARS-CoV-2 testing data. There were 35 347 donor specimen SARS-CoV-2 tests, 77.5% upper respiratory samples, 94.6% polymerase chain reaction tests, and 1.2% SARS-CoV-2-positive tests. Donor age, gender, history of hypertension, and diabetes were similar by SARS-CoV-2 status, while positive SARS-CoV-2 donors were more likely African-American, Hispanic, and donors after cardiac death (p-values <.01). Recipient demographic characteristics were similar by donor SARS CoV-2 status. Adjusted donor kidney discard (odds ratio = 2.08, 95% confidence interval [CI] 1.66-2.61) was higher for SARS-CoV-2-positive donors while donor liver (odds ratio = 0.44, 95% CI 0.33-0.60) and heart recovery (odds ratio = 0.44, 95% CI 0.31-0.63) were significantly reduced. Overall post-transplant graft survival for kidney, liver, and heart recipients was comparable by donor SARS-CoV-2 status. Cumulatively, there has been significantly lower utilization of SARS-CoV-2 donors with no evidence of reduced recipient graft survival with variations in practice over time.

 

Comments made by Cale Kassel M.D., FASA  

Summary:

When the COVID-19 pandemic began, there were obvious concerns among the transplant community. First and foremost, how could we protect patients following transplant and while waiting from transplant. As our understanding of COVID-19 evolved, so to did our ability to manage the disease in organ transplantation. The question of utilizing COVID-positive organs for transplantation emerged. Schold, et al reviewed SRTR data to look at utilization of COVID-positive organs (kidney, liver, and heart) from early in the pandemic to present. Several key findings emerged as they evaluated the data. 

First, they found utilizing COVID-positive grafts did not demonstrate worse outcomes for patients. Graft survival was similar between COVID-positive and COVID-negative grafts for kidney (95.5% vs. 95.3%), liver (93.9% vs. 97.0%), and heart (92.8% vs. 96.7%). 

Second, utilization of COVID-positive donors remained low. Recovery of COVID-positive organs was lower for kidneys, livers, and hearts. Additionally, discard of recovered grafts were lower in COVID-positive grafts. However, kidney graft discard rate of COVID-positive grafts was lower in the later study period (Dec 2020-April 2021) compared to the early study period (March 2020-November 2020). The overall rate of discard for COVID-positive kidneys was still lower than COVID-negative. Heart and liver discard rates were lower in COVID-positive donors as well. 

As we continue to learn more about the effect of transplantation of COVID-positive organs, we can continue to optimize patients and grafts to improve outcomes. Early data from this study and others suggests COVID-positive grafts can provide a safe option for patients awaiting transplantation.

References:

Schold JD, Koval CE, Wee A, Eltemamy M, Poggio ED. Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States. American Journal of Transplantation 2022;22(9):2217-2227. DOI: https://doi.org/10.1111/ajt.17126.

Filed Under: Article of the Month, Education

SATA Southeastern Regional Meeting – Thoracic Transplantation

November 21, 2022 By pacainc Leave a Comment

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

Filed Under: Lectures, Meeting, Regional Meeting Media

SATA Southeastern Regional Meeting – SATA Presidential Address

November 21, 2022 By pacainc Leave a Comment

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

Filed Under: Lectures, Meeting, Regional Meeting Media

SATA Southeastern Regional Meeting – Abdominal Transplantation

November 21, 2022 By pacainc Leave a Comment

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

Filed Under: Lectures, Meeting, Regional Meeting Media

SATA MidState Regional Meeting – Case Presentations

September 29, 2022 By pacainc

SATA MidState Regional Meeting – Case Presentations

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

 

 

Filed Under: Lectures, Meeting, Regional Meeting Media

SATA MidState Regional Meeting – Current Dilemmas in Transplantation Session

September 29, 2022 By pacainc

SATA MidState Regional Meeting – Current Dilemmas in Transplantation Session

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

 

 

Filed Under: Lectures, Meeting, Regional Meeting Media

SATA MidState Regional Meeting – Cardiopulmonary Considerations in Transplantation Session

September 29, 2022 By pacainc

SATA MidState Regional Meeting – Cardiopulmonary Considerations in Transplantation Session

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

 

 

Filed Under: Lectures, Meeting, Regional Meeting Media

SATA MidState Regional Meeting – SATA Address

September 29, 2022 By pacainc

SATA MidState Regional Meeting – SATA Address

This content is for SATA Members only

Login To have access to the Content!

Username:
Password:
Register
Lost your password?

 

Filed Under: Lectures, Meeting, Regional Meeting Media

September 2022 – Article of the Month

September 28, 2022 By pacainc

Factors Associated With Postreperfusion Syndrome in Living Donor Liver Transplantation: A Retrospective Study

Abstract

Background: Postreperfusion syndrome (PRS) after portal vein reperfusion during liver transplantation (LT) has been reported to cause rapid hemodynamic changes and is associated with a prolonged postoperative hospital stay, renal failure, and increased mortality. Although there are some reports on risk factors for PRS in brain-dead donor LT, there are a few reports on those in living donor LT. Therefore, we retrospectively reviewed the factors associated with PRS to contribute to the anesthetic management so as to reduce PRS during living donor LT.

Methods: After approval by the ethics committee of our institution, 250 patients aged ≥20 years who underwent living donor LT at our institution between January 2013 and September 2018 were included in the study. A decrease in mean arterial pressure of ≥30% within 5 minutes after portal vein reperfusion was defined as PRS, and estimates and odds ratio (OR) for PRS were calculated using logistic regression. The backward method was used for variable selection in the multivariable analysis.

Results: Serum calcium ion concentration before reperfusion (per 0.1 mmol/L increase; OR, 0.74; 95% confidence interval (CI), 0.60-0.95; P < .001), preoperative echocardiographic left ventricular end-diastolic diameter (per 1-mm increase: OR, 0.90; 95% CI, 0.85-0.95; P < .001, men [versus women: OR, 2.45; 95% CI, 1.26-4.75; P = .008]), mean pulmonary artery pressure before reperfusion (restricted cubic spline, P = .003), anhepatic period (restricted cubic spline, P = .02), and graft volume to standard liver volume ratio (restricted cubic spline, P = .03) were significantly associated with PRS.

Conclusions: In living donor LT, male sex and presence of small left ventricular end-diastolic diameter, large graft volume, and long anhepatic period are associated with PRS, and a high calcium ion concentration and low pulmonary artery pressure before reperfusion are negatively associated with PRS.

Comments by Scott Byram M.D.

Summary:

Hemodynamic management is often difficult and complex during orthotopic liver transplantation (OLT).  One stage that can be particularly challenging to the anesthesiologist is the initiation of the neohepatic stage signaled by reperfusion of the liver graft.  Post reperfusion syndrome (PRS) is known to cause rapid hemodynamic changes and is seen within minutes of opening the portal vein.  The exact mechanism of PRS is still not understood, but is most likely multifactorial.  PRS has been associated with several poor postoperative outcomes including renal failure, increased length of stay, and increased mortality. 

                In this retrospective study, the authors sought to identify risk factors for developing PRS after  living donor (LD) OLT.  Most prior studies on this topic have examined PRS with brain death donors.  For this study, PRS was defined as a decrease in mean arterial pressure by more than 30% within 5 minutes of reperfusion that persisted for longer than 1 minute.  250 charts of LD OLT recipients were reviewed.  Of these patients, 73 (29%) met the criteria for PRS. There were no significant baseline differences in sex, age, liver function, general condition, comorbidities, blood pressure, or medication between the two groups (PRS vs. non-PRS).  Through multi-variable statistical analysis, the authors identified five significant risk factors for developing PRS.  Characteristics associated with increased risk for PRS were: male sex, low left ventricular end-diastolic diameter on pre-op TTE, prolonged anhepatic duration, large graft volume, low ionized calcium just prior to reperfusion, and high mean pulmonary artery pressure (mPAP) just prior to reperfusion.    These last two risk factors are particularly interesting because the anesthesiologist is able to modify both calcium concentration and mPAP prior to reperfusion, therefore potentially decreasing the risk for PRS.

                The authors went on to speculate as to why these risk factors play a role in the development of PRS.  However, they strongly cautioned readers not to assume that these associations were causative given the retrospective nature of this study.  The ultimate conclusion of this paper was that these five factors could aid in predicting the probability of PRS, but randomized control trials would be needed to establish preventative strategies.

References

  1. Umehara K, Karashima Y, Yoshizumi T, Yamaura K. Factors Associated With Postreperfusion Syndrome in Living Donor Liver Transplantation: A Retrospective Study. Anesth Analg. 2022 Aug 1;135(2):354-361. doi: 10.1213/ANE.0000000000006002. Epub 2022 Jul 5. PMID: 35343925.

 

Filed Under: Article of the Month, Education, Lectures

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

Information for Authors

Upcoming Events

Mar 25
9:00 am - 2:00 pm

2023 Tristate SATA Regional Meeting

Apr 17
8:00 am - 3:00 pm

SATA 2023 Annual Meeting

View Calendar

President’s Message

Tetsuro Sakai MD

Tetsuro Sakai MD, PhD, MHA, FASA

SATA President

Read more

Contact Us

Copyright © 2023 Society for the Advancement of Transplant Anesthesia (SATA) - Powered by: Top Shelf Design